ACLX insider trading
HealthcareArcellx, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Arcellx, Inc.
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Company website: www.arcellx.com
ACLX insider activity at a glance
FilingIQ has scored 447 insider transactions for ACLX since Feb 8, 2022. The most recent filing in our index is dated Apr 28, 2026.
Across the full history, 7 open-market purchases
and 188 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ACLX insider trades is 62.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ACLX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ACLX
13F funds holding ACLX
Frequently asked
- How many insider trades does FilingIQ track for ACLX?
- FilingIQ tracks 447 Form 4 insider transactions for ACLX (Arcellx, Inc.), covering filings from Feb 8, 2022 onwards. 86 of those were filed in the last 90 days.
- Are ACLX insiders net buyers or net sellers?
- Across the full Form 4 history for ACLX, 7 transactions (2%) were open-market purchases and 188 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ACLX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ACLX in?
- Arcellx, Inc. (ACLX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.99B.
Methodology & sources
Every ACLX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.